RT Journal Article
T1 A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.
A1 Eslam, Mohammed
A1 Newsome, Philip N
A1 Sarin, Shiv K
A1 Anstee, Quentin M
A1 Targher, Giovanni
A1 Romero-Gomez, Manuel
A1 Zelber-Sagi, Shira
A1 Wai-Sun Wong, Vincent
A1 Dufour, Jean-François
A1 Schattenberg, Jörn M
A1 Kawaguchi, Takumi
A1 Arrese, Marco
A1 Valenti, Luca
A1 Shiha, Gamal
A1 Tiribelli, Claudio
A1 Yki-Järvinen, Hannele
A1 Fan, Jian-Gao
A1 Grønbæk, Henning
A1 Yilmaz, Yusuf
A1 Cortez-Pinto, Helena
A1 Oliveira, Claudia P
A1 Bedossa, Pierre
A1 Adams, Leon A
A1 Ming-Hua, Zheng
A1 Fouad, Yasser
A1 Wah-Kheong, Chan
A1 Mendez-Sanchez, Nahum
A1 Sang Hoon, Ahn
A1 Castera, Laurent
A1 Bugianesi, Elisabetta
A1 Ratziu, Vlad
A1 George, Jacob
K1 Cirrhosis
K1 Diabetes
K1 Diagnostic criteria
K1 MAFLD
K1 Metabolic
K1 NAFLD
K1 Obesity
K1 Steatohepatitis
AB The exclusion of other chronic liver diseases including "excess" alcohol intake has until now been necessary to establish a diagnosis of metabolic dysfunction-associated fatty liver disease (MAFLD). However, given our current understanding of the pathogenesis of MAFLD and its rising prevalence, "positive criteria" to diagnose the disease are required. In this work, a panel of international experts from 22 countries propose a new definition for the diagnosis of MAFLD that is both comprehensive and simple, and is independent of other liver diseases. The criteria are based on evidence of hepatic steatosis, in addition to one of the following three criteria, namely overweight/obesity, presence of type 2 diabetes mellitus, or evidence of metabolic dysregulation. We propose that disease assessment and stratification of severity should extend beyond a simple dichotomous classification to steatohepatitis vs. non-steatohepatitis. The group also suggests a set of criteria to define MAFLD-associated cirrhosis and proposes a conceptual framework to consider other causes of fatty liver disease. Finally, we bring clarity to the distinction between diagnostic criteria and inclusion criteria for research studies and clinical trials. Reaching consensus on the criteria for MAFLD will help unify the terminology (e.g. for ICD-coding), enhance the legitimacy of clinical practice and clinical trials, improve clinical care and move the clinical and scientific field of liver research forward.
PB Elsevier BV
YR 2020
FD 2020-04-08
LK http://hdl.handle.net/10668/15358
UL http://hdl.handle.net/10668/15358
LA en
NO Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020 Jul;73(1):202-209.
DS RISalud
RD Apr 4, 2025